Methotrexate improves the health-related quality of life of children with juvenile idiopathic arthritis.

Autoria(s): Céspedes-Cruz A.; Gutiérrez-Suárez R.; Pistorio A.; Ravelli A.; Loy A.; Murray K.J.; Gerloni V.; Wulffraat N.; Oliveira S.; Walsh J.; Penades I.C.; Alpigiani M.G.; Lahdenne P.; Saad-Magalhães C.; Cortis E.; Lepore L.; Kimura Y.; Wouters C.; Martini A.; Ruperto N.; Pediatric Rheumatology International Trials Organization (PRINTO)
Data(s)

2008
Identificador

https://serval.unil.ch/?id=serval:BIB_BB75058D37D9

isbn:1468-2060[electronic], 0003-4967[linking]

pmid:17875547

doi:10.1136/ard.2007.075895

isiid:000253443600006
Idioma(s)

en
Fonte

Annals of the Rheumatic Diseases, vol. 67, no. 3, pp. 309-314
Palavras-Chave #Adolescent; Antirheumatic Agents/therapeutic use; Arthritis, Juvenile Rheumatoid/drug therapy; Arthritis, Juvenile Rheumatoid/physiopathology; Child; Child, Preschool; Disability Evaluation; Dose-Response Relationship, Drug; Female; Humans; Immunosuppressive Agents/therapeutic use; Male; Methotrexate/therapeutic use; Quality of Life; Recovery of Function; Severity of Illness Index; Treatment Outcome
Tipo

info:eu-repo/semantics/article

article
Acesso ao item digital